Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy

Melanoma Research

Volumn 6, Issue 2, 1996, Pages 173-178

  Keilholz, U ^a   Scheibenbogen, C ^a   Sommer, M ^a   Pritsch, M ^a   Geuke, A M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

immunotherapy; metastatic melanoma; prognostic factors

Indexed keywords

ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0029783592     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199604000-00013     Document Type: Article

References (17)

1. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-1874.
2. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon 2A in cancer patients: a phase 1 study. J Clin Oncol 1989; 7: 1726-1732.
3. Bukowski RM, Murthy S, Sergi J, et al. Phase 1 trial of continuous infusion recombinant interleukin-2 and intermittant recombinant interferon-a2a: clinical effects. J Biol Response Modif 1990; 9 538-545.
4. Sznol M, Mier JW, Sparano J, et al. A phase 1 study of high-dose interleukin-2 in combination with interferon-a2b. J Biol Response Modif 1990; 9: 529-537.
5. Keilholz U, Scheibenbogen C, Tilgen W, et al. Interferon-a and Interleukin-2 in the treatment of malignant melanoma: a comparison of two phase II trials. Cancer 1993; 72: 607-614.
6. Keilholz U, Scheibenbogen C, Stoelben E, et al. Immunotherapy of metastatic melanoma with IFNα and IL-2: pattern of progression in responders and patients with stable disease without or with resection of residual lesions. Eur J Cancer 1994; 30A: 955-958.
7. Schneider RJ, Seibert K, Passe S. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139-145.
8. Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma. Am J Med 1983; 74: 786-794.
9. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and IL-2. J Clin Oncol 1994; 12: 1475-1483.
10. Marincola MF, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with IL-2 based immunotherapy. Cancer Res 1992; 52: 6561-6566.
11. Scheibenbogen C, Keilholz U, Mytilineos J, et al. HLA class 1 alleles and responsiveness to immunotherapy with IFNa and IL-2. Melanoma Research 1994, 4: 191-194
12. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma J Clin Oncol 1992; 10: 1338-1343.
13. Scheibenbogen C, Keilholz U, Hunstein W. Vitiligo-like lesions following immunotherapy with IFNa/IL-2 in melanoma patients. Eur J Cancer 1994; 30A: 1209-1211.
14. Blay JY, Favrot MC, Negrier S, et al. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990; 50: 2371-2374.
15. Balch CM, Soong S, Shaw HM, el at. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma, 2nd edn. Philadelphia, PA: Lippincott, 1992: 165-187.
16. Einhorn LH, Burgess MA, Vallejos C, et al. Prognostic correlations and response to treatment in advanced malignant melanoma. Cancer Res 1974; 34: 1995-2004.
17. Karakousis CP, Temple DF, Moore R and Ambrus JL. Prognostic parameters in recurrent malignant melanoma. Cancer 1983; 52: 575-579.